Litoxetine

Litoxetine
Clinical data
Other names	SL 81-0385; IXA-001
ATC code	None;
Identifiers
	IUPAC name 4-(naphthalen-2-ylmethoxy)piperidine;
CAS Number	86811-09-8;
PubChem CID	65650;
ChemSpider	59087;
UNII	9980ST005G;
ChEMBL	ChEMBL471036;
CompTox Dashboard (EPA)	DTXSID30235828 ;
Chemical and physical data
Formula	C16H19NO
Molar mass	241.334 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C3CNCCC3OCc2cc1ccccc1cc2;

Litoxetine (developmental code names SL 81-0385, IXA-001) is an antidepressant which was under clinical development for the treatment of depression in the early 1990s but was never marketed.^[1]^[2] It acts as a potent serotonin reuptake inhibitor (K_i for SERTTooltip serotonin transporter = 7 nM) and modest 5-HT₃ receptor antagonist (K_i = 315 nM).^[3]^[4] It has antiemetic activity, and unlike the selective serotonin reuptake inhibitors (SSRIs), appears to have a negligible incidence of nausea and vomiting.^[5] The drug is structurally related to indalpine.^[4] Development of litoxetine for depression was apparently ceased in the late 1990s.^[1] However, as of March 2017, development of litoxetine has been reinitiated and the drug is now in the phase II stage for the treatment of urinary incontinence.^[1]